BioSpace News Archive

Studies presented at two leading breast imaging conferences demonstrate ProFound AI helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors.

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of David Nichols as Chief Technical Officer.

PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced today the publication of a new study titled, “Effects of Bovine Colostrum with or without Egg on In Vitro Bacterial-Induced Intestinal Damage with Relevance for SIBO and Infectious Diarrhea,” in the peer-reviewed journal Nutrients on March 22, 2021.

PharmCADD, a Korean Artificial Intelligence (AI) and Physics-based drug discovery company announced that it has finished USD 16 million series B funding on March 31, 2021.

Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it will release its third quarter 2021 financial results for the period ended March 26, 2021 after market close on Monday, May 3, 2021. On that day, management will hold a conference call and webcas

The face shield market may reach for the escalator to great growth opportunities across the forecast period of 2019-2029. The COVID-19 pandemic may serve as the prime reason for the growth of the face shield market.

Funding will support first-in-man intravenous studies to tackle antibiotic resistant Pseudomonas aeruginosa in ventilated associated pneumonia

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate.

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the initiation of dosing in a Phase 2 proof-of-concept trial in patients with head and neck squamous cell carcinoma.